CN102164603B - 用于治疗丛集性头痛症的方法和试剂盒 - Google Patents

用于治疗丛集性头痛症的方法和试剂盒 Download PDF

Info

Publication number
CN102164603B
CN102164603B CN200980136477.XA CN200980136477A CN102164603B CN 102164603 B CN102164603 B CN 102164603B CN 200980136477 A CN200980136477 A CN 200980136477A CN 102164603 B CN102164603 B CN 102164603B
Authority
CN
China
Prior art keywords
cluster headache
main body
headache disease
application according
pharmaceutical salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980136477.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102164603A (zh
Inventor
约翰·H·哈尔佩恩
托尔斯滕·哈里·约翰内斯·帕西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medizinische Hochschule Hannover
Mclean Hospital Corp
Original Assignee
Medizinische Hochschule Hannover
Mclean Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover, Mclean Hospital Corp filed Critical Medizinische Hochschule Hannover
Publication of CN102164603A publication Critical patent/CN102164603A/zh
Application granted granted Critical
Publication of CN102164603B publication Critical patent/CN102164603B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN200980136477.XA 2008-09-17 2009-09-04 用于治疗丛集性头痛症的方法和试剂盒 Expired - Fee Related CN102164603B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9777308P 2008-09-17 2008-09-17
US61/097,773 2008-09-17
PCT/US2009/055971 WO2010033392A2 (en) 2008-09-17 2009-09-04 Methods and kits for treating cluster headache disorders

Publications (2)

Publication Number Publication Date
CN102164603A CN102164603A (zh) 2011-08-24
CN102164603B true CN102164603B (zh) 2015-11-25

Family

ID=42040074

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980136477.XA Expired - Fee Related CN102164603B (zh) 2008-09-17 2009-09-04 用于治疗丛集性头痛症的方法和试剂盒

Country Status (10)

Country Link
US (2) US8415371B2 (enExample)
EP (1) EP2331100B1 (enExample)
JP (1) JP5690732B2 (enExample)
CN (1) CN102164603B (enExample)
BR (1) BRPI0918623A2 (enExample)
CA (1) CA2737135C (enExample)
GB (1) GB2475660B (enExample)
IL (1) IL211714A (enExample)
MX (1) MX2011002883A (enExample)
WO (1) WO2010033392A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859579B2 (en) 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
CN102164603B (zh) * 2008-09-17 2015-11-25 麦克莱恩医院 用于治疗丛集性头痛症的方法和试剂盒
EP4230195A1 (en) * 2019-03-07 2023-08-23 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
WO2021195427A1 (en) * 2020-03-25 2021-09-30 Ch Tac, Llc 2-bromo-lysergic acid diethylamide for substance abuse
WO2022133604A1 (en) * 2020-12-22 2022-06-30 Betterlife Pharma Inc. Methods of treating mental or mood disorders using 2-bromo-lsd
US20240180894A1 (en) * 2021-03-22 2024-06-06 Betterlife Pharma Inc. Methods of treating mental and/or mood disorders using 2-bromo-lsd alone or in combination with a mtor inhibitor
EP4329759A4 (en) 2021-04-30 2025-07-16 Mind Medicine Inc CRYSTALLINE FORMS OF LSD SALTS
EP4387624A4 (en) 2021-08-19 2025-07-30 Mind Medicine Inc Immediate Release Formulations of Diethylamide of D-Lysergic Acid for Therapeutical Applications
IL311602A (en) * 2021-09-20 2024-05-01 Betterlife Pharma Inc Lsd derivatives, synthesis & method for treatment of diseases and disorders
EP4630418B1 (en) * 2022-12-31 2026-03-18 Ceruvia Lifesciences LLC Salts of 2-bromolysergic acid diethylamide
WO2024145604A2 (en) * 2022-12-31 2024-07-04 Ceruvia Lifesciences Llc Process for synthesizing 2-bromolysergic acid diethylamide via controlled hydrolysis of bromocriptine
US20240228479A1 (en) 2022-12-31 2024-07-11 Ceruvia Lifesciences Llc Process for synthesizing 2-bromolysergic acid diethylamide via controlled bromination of lysergic acid

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3228959A (en) * 1962-01-16 1966-01-11 Geigy Chem Corp Quaternary salts of certain indolealkylamines and therapeutic uses thereof
US4524072A (en) * 1984-06-18 1985-06-18 Zivin Justin A Reduction of stroke damage
GB8618700D0 (en) * 1986-07-31 1986-09-10 Beecham Group Plc Compounds
EP0255297B1 (en) * 1986-07-31 1993-04-21 Beecham Group Plc Azabicyclic compounds, process for their preparation, and their pharmaceutical use
EP1478400A1 (en) * 2002-02-26 2004-11-24 Ortho-McNeil Pharmaceutical, Inc. Therapy for the treatment of migraine comprising anticonvulsant derivatives and antimigraine agents
WO2004112723A2 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US8859579B2 (en) * 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
CN102164603B (zh) * 2008-09-17 2015-11-25 麦克莱恩医院 用于治疗丛集性头痛症的方法和试剂盒

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Federigo Sicuteri.MIGRAINE, A CENTRAL BIOCHEMICAL DYSNOCICEPTION.《Headache》.1976,第16卷145-159. *
J.A.HARVEY et al..Effects of d-Lysergic Acid Diethylamide, d-2-Bromolysergic Acid Diethylamide, dl-2,5-Dimethoxy-4-Methylamphetamine and d-Amphetamine on Classical Conditioning of the Rabbit Nictitating Membrane Response.《The journal of Pharmacology and Experimental Therapeutics》.1982,第289-294页. *
R.Andrew Sewell et al.Response of cluster headache to psilocybin and LSD.《Neurology》.2006,第66卷1920-1922. *

Also Published As

Publication number Publication date
US20110104275A1 (en) 2011-05-05
JP2012502909A (ja) 2012-02-02
MX2011002883A (es) 2011-04-21
EP2331100A2 (en) 2011-06-15
US20130252996A1 (en) 2013-09-26
HK1161098A1 (zh) 2012-08-24
GB201104907D0 (en) 2011-05-04
CA2737135A1 (en) 2010-03-25
CN102164603A (zh) 2011-08-24
EP2331100A4 (en) 2012-04-25
GB2475660A (en) 2011-05-25
WO2010033392A2 (en) 2010-03-25
GB2475660B (en) 2013-04-17
BRPI0918623A2 (pt) 2015-12-01
CA2737135C (en) 2017-07-11
US8415371B2 (en) 2013-04-09
WO2010033392A3 (en) 2010-06-17
JP5690732B2 (ja) 2015-03-25
EP2331100B1 (en) 2014-07-16
IL211714A (en) 2016-04-21
IL211714A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
CN102164603B (zh) 用于治疗丛集性头痛症的方法和试剂盒
Grassi et al. Efficacy and tolerability profile of Nebivolol vs Atenolol in mild‐to‐moderate essential hypertension: Results of a double‐blind randomized multicentre trial
US11083735B2 (en) Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
EP3930841A1 (en) A formulation for improving seizure control
CN119072304A (zh) 用于治疗cns相关障碍的神经活性类固醇
US20240366582A1 (en) Treatment of raynaud's disease
WO2011019845A1 (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions
McGeeney Topiramate in the treatment of cluster headache
US20200129528A1 (en) Methods for treating blood pressure conditions using aminosterol compositions
US20180221380A1 (en) Use of 5H-Dibenz/b,f/Azepine-5-Carboxamide Derivatives for Treating Fibromyalgia
EP3096790B1 (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
JP2005132799A (ja) 本態性振戦の予防・治療剤
HK1161098B (en) Methods and kits for treating cluster headche disorders
Sarelic et al. Nisoldipine CC: clinical experience in hypertension
AU2006236602B2 (en) Pharmacological treatment for sleep apnea
US8680145B1 (en) Compositions and methods for treatment of fear of medical procedures
Susic et al. 1085-194 Eplerenone improves coronary hemodynamics and reduces cardiac fibrosis in aging spontaneously hypertensive rats
TW201023853A (en) Method of treating sleep disorders using eplivanserin
JP2005533046A (ja) 鎮痛薬の作用を増強するためにオピオイド鎮痛薬と併用するデバゼピドの使用
Breivik et al. Antiepileptics, antidepressants, and local anesthetic drugs
CA2908706A1 (en) Treatments involving eslicarbazepine or eslicarbazepine acetate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1161098

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1161098

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151125

Termination date: 20210904